Soluble T-cell receptors produced in human cells for targeted delivery

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Walseng, Even ^a,c   Wälchli, Sébastien ^a   Fallang, Lars Egil ^a,d   Yang, Weiwen ^a,b   Vefferstad, Anette ^a,b   Areffard, Ali ^a   Olweus, Johanna ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d Biogenidec   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; HLA A ANTIGEN; HLA ANTIGEN; MAGNETIC NANOPARTICLE; MELAN A; STREPTAVIDIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; HYBRID PROTEIN; IMMUNOTOXIN; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE; PROTEIN BINDING; RIBOSOME INACTIVATING PROTEIN 1; SAPORIN;

ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CELL LABELING; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTERNALIZATION; MOLECULAR RECOGNITION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RIBOSOME; SUPERNATANT; TARGET CELL; AMINO ACID SEQUENCE; CELL LINE; CHEMISTRY; DRUG DELIVERY SYSTEM; GENETICS; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PROCEDURES; PROTEIN MULTIMERIZATION; SOLUBILITY;

AMINO ACID SEQUENCE; BASE SEQUENCE; CELL LINE; CLONING, MOLECULAR; DRUG DELIVERY SYSTEMS; HEK293 CELLS; HELA CELLS; HUMANS; IMMUNOTOXINS; MART-1 ANTIGEN; PEPTIDES; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; SOLUBILITY;

EID: 84928905266     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119559     Document Type: Article

References (48)

1. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature. 1988; 334(6181): 395-402.PMID: 3043226.
2. Gregoire C, Rebai N, Schweisguth F, Necker A, Mazza G, Auphan N, et al. Engineered secreted T-cell receptor alpha beta heterodimers. Proc Natl Acad Sci U S A. 1991; 88(18):8077-81. PMID: 1716770.
3. Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA, et al. An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science. 1996; 274(5285): 209-19. PMID: 8824178.
4. Molloy PE, Sewell AK, Jakobsen BK. Soluble T cell receptors: novel immunotherapies. Curr Opin Pharmacol. 2005; 5(4):438-43. PMID: 15939669.
5. Richman SA, Kranz DM. Display, engineering, and applications of antigen-specific T cell receptors. Biomol Eng. 2007; 24(4):361-73. PMID: 17409021.
6. Stone JD, Chervin AS, Aggen DH, Kranz DM. T cell receptor engineering. Methods Enzymol. 2012; 503:189-222. PMID: 22230570. doi: 10.1016/B978-0-12-396962-0.00008-2
7. Pecorari F, Tissot AC, Pluckthun A. Folding, heterodimeric association and specific peptide recognition of a murine alphabeta T-cell receptor expressed in Escherichia coli. J Mol Biol. 1999; 285(4):1831-43. PMID: 9917415.
8. Boulter JM, Glick M, Todorov PT, Baston E, Sami M, Rizkallah P, et al. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng. 2003; 16(9):707-11. PMID: 14560057.
9. van Boxel GI, Stewart-Jones G, Holmes S, Sainsbury S, Shepherd D, Gillespie GM, et al. Some lessons from the systematic production and structural analysis of soluble (alpha)(beta) T-cell receptors. J Immunol Methods. 2009; 350(1-2):14-21. PMID: 19715696. doi: 10.1016/j.jim.2009.09.001
10. Bridgeman JS, Sewell AK, Miles JJ, Price DA, Cole DK. Structural and biophysical determinants of alphabeta T-cell antigen recognition. Immunology. 2012; 135(1):9-18. PMID: 22044041. doi: 10.1111/j.1365-2567.2011.03515.x
11. Macdonald WA, Chen Z, Gras S, Archbold JK, Tynan FE, Clements CS, et al. T cell allorecognition via molecular mimicry. Immunity. 2009; 31(6):897- 908. PMID: 20064448. doi: 10.1016/j.immuni.2009.09.025
12. Tikhonova AN, Van Laethem F, Hanada K, Lu J, Pobezinsky LA, Hong C, et al. alphabeta T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities. Immunity. 2012; 36(1):79-91. PMID: 22209676. doi: 10.1016/j.immuni.2011.11.013
13. Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem. 2012. PMID: 22549784.
14. Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, et al. Monoclonal TCR-redirected tumor cell killing. Nat Med. 2012. PMID: 22561687.
15. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med. 2008; 14(12):1390-5. PMID: 18997777. doi: 10.1038/nm.1779
16. Card KF, Price-Schiavi SA, Liu B, Thomson E, Nieves E, Belmont H, et al. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunol Immunother. 2004; 53(4):345-57. PMID: 14610621.
17. Chung S, Wucherpfennig KW, Friedman SM, Hafler DA, Strominger JL. Functional three-domain single-chain T-cell receptors. Proc Natl Acad Sci U S A. 1994; 91(26):12654-8. PMID: 7809095.
18. Epel M, Ellenhorn JD, Diamond DJ, Reiter Y. A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells. Cancer Immunol Immunother. 2002; 51(10):565-73. PMID: 12384808.
19. Laugel B, Boulter JM, Lissin N, Vuidepot A, Li Y, Gostick E, et al. Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition. J Biol Chem. 2005; 280(3):1882-92. PMID: 15531581.
20. Mosquera LA, Card KF, Price-Schiavi SA, Belmont HJ, Liu B, Builes J, et al. In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein. J Immunol. 2005; 174(7):4381-8. PMID: 15778403.
21. de Felipe P, Luke GA, Hughes LE, Gani D, Halpin C, Ryan MD. E unum pluribus: multiple proteins from a self-processing polyprotein. Trends Biotechnol. 2006; 24(2):68-75. PMID: 16380176.
22. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol. 2004; 22(5):589-94. PMID: 15064769.
23. Birnbaum ME, Mendoza JL, Sethi DK, Dong S, Glanville J, Dobbins J, et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell. 2014; 157(5):1073-87. Epub 2014/05/27. doi: 10.1016/j.cell.2014.03.047 PMID: 24855945; PubMed Central PMCID: PMC4071348.
24. Walchli S, Loset GA, Kumari S, Nergard Johansen J, Yang W, Sandlie I, et al. A practical approach to T-cell receptor cloning and expression. PLoS One. 2011; 6(11):e27930. PMID: 22132171. doi: 10.1371/journal.pone.0027930
25. Moll R, Cook LH, Saul J. Church programs as a first clinical experience. Nurse Educ. 2001; 26(3): 122-4. Epub 2002/07/30. PMID: 12144323.
26. Mitaksov V, Truscott SM, Lybarger L, Connolly JM, Hansen TH, Fremont DH. Structural engineering of pMHC reagents for T cell vaccines and diagnostics. Chem Biol. 2007; 14(8):909-22. PMID: 17719490.
27. Stronen E, Abrahamsen IW, Gaudernack G, Walchli S, Munthe E, Buus S, et al. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells. Scand J Immunol. 2009; 69(4):319-28. PMID: 19284496. doi: 10.1111/j.1365-3083.2008.02223.x
28. Johnson LA, Heemskerk B, Powell DJ Jr, Cohen CJ, Morgan RA, Dudley ME, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol. 2006; 177(9):6548-59. PMID: 17056587.
29. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998; 160(4):1750-8. Epub 1998/02/20. PMID: 9469433.
30. Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol. 2008; 180(9):6116-31. PMID: 18424733.
31. Borbulevych OY, Santhanagopolan SM, Hossain M, Baker BM. TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J Immunol. 2011; 187(5): 2453-63. PMID: 21795600. doi: 10.4049/jimmunol.1101268
32. Yu YY, Netuschil N, Lybarger L, Connolly JM, Hansen TH. Cutting edge: single-chain trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific T cells and B cells. J Immunol. 2002; 168(7):3145-9. PMID: 11907065.
33. Abrahamsen IW, Stronen E, Walchli S, Johansen JN, Kjellevoll S, Kumari S, et al. Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia. 2010; 24 (11):1901-9. PMID: 20844564. doi: 10.1038/leu.2010.186
34. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007; 67(8): 3898-903. PMID: 17440104.
35. Hahn M, Nicholson MJ, Pyrdol J, Wucherpfennig KW. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nature Immunology. 2005; 6(5):490-6. doi: 10.1038/Ni1187 PMID: ISI:000228634300021.
36. Willcox BE, Gao GF, Wyer JR, O'Callaghan CA, Boulter JM, Jones EY, et al. Production of soluble alphabeta T-cell receptor heterodimers suitable for biophysical analysis of ligand binding. Protein Sci. 1999; 8(11):2418-23. Epub 1999/12/14. doi: 10.1110/ps.8.11.2418 PMID: 10595544; PubMed Central PMCID: PMC2144200.
37. Donaldson JG, Williams DB. Intracellular assembly and trafficking of MHC class I molecules. Traffic. 2009; 10(12):1745-52. PMID: 19761542. doi: 10.1111/j.1600-0854.2009.00979.x
38. Ng TB, Wong JH, Wang H. Recent progress in research on ribosome inactivating proteins. Curr Protein Pept Sci. 11(1):37-53. PMID: 20201806.
39. Leisegang M, Engels B, Meyerhuber P, Kieback E, Sommermeyer D, Xue SA, et al. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med (Berl). 2008; 86(5):573-83. PMID: 18335188. doi: 10.1007/s00109-008-0317-3
40. Chang HC, Bao Z, Yao Y, Tse AG, Goyarts EC, Madsen M, et al. A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments. Proc Natl Acad Sci U S A. 1994; 91(24):11408-12. PMID: 7972074.
41. Ding YH, Baker BM, Garboczi DN, Biddison WE, Wiley DC. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity. 1999; 11(1):45-56. Epub 1999/08/06. PMID: 10435578.
42. Baker BM, Gagnon SJ, Biddison WE, Wiley DC. Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: implications for TCR signaling. Immunity. 2000; 13(4):475-84. Epub 2000/11/09. PMID: 11070166.
43. Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am. 26(3): 447-81, vii. PMID: 22520975. doi: 10.1016/j.hoc.2012.02.013
44. Chlewicki LK, Holler PD, Monti BC, Clutter MR, Kranz DM. High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J Mol Biol. 2005; 346(1):223-39. PMID: 15663940.
45. Dunn SM, Rizkallah PJ, Baston E, Mahon T, Cameron B, Moysey R, et al. Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci. 2006; 15(4):710-21. PMID: 16600963.
46. Holler PD, Holman PO, Shusta EV, O'Herrin S, Wittrup KD, Kranz DM. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci U S A. 2000; 97(10):5387-92. PMID: 10779548.
47. Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol. 2005; 23(3):349-54. PMID: 15723046.
48. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988; 332(6162):323-7. Epub 1988/03/24. doi: 10.1038/332323a0 PMID: 3127726.